<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02180841</url>
  </required_header>
  <id_info>
    <org_study_id>PKE SOY</org_study_id>
    <nct_id>NCT02180841</nct_id>
  </id_info>
  <brief_title>Effect of Soy on HDL-C Function, Central Blood Pressure, and Arterial Stiffness</brief_title>
  <acronym>SOY</acronym>
  <official_title>Effect of Soy on HDL-C Function, Central Blood Pressure, and Arterial Stiffness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DuPont Nutrition and Health</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Penn State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the proposed pilot study is to evaluate the effects of a soy protein isolate
      with naturally occurring isoflavones on the properties of HDL-C (total HDL-C, HDL particle
      size and HDL function), central blood pressure, and indices of arterial stiffness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose to conduct a randomized three-period, crossover study to evaluate
      the effect of soy protein supplementation on HDL function. To ensure that there are no
      effects of treatment order on outcome measures, subjects will be randomized to a treatment
      sequence. Healthy males and females (n = 20; 35 to 60 years of age) with systolic blood
      pressure greater than 120 mm Hg and/or diastolic blood pressure greater than 80 mm Hg will be
      recruited for this study. Subjects will undergo 3 treatment periods in random order. These
      treatment periods will include: A) 25 g/d soy protein powder; B) 50 g/d soy protein powder;
      C) 0 g/d protein powder (control). Each treatment will be provided for 6 weeks separated by a
      2-week break between treatment periods. All subjects will be encouraged to maintain body
      weight and physical activity levels during the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HDL function (RCT) as measured by cholesterol efflux.</measure>
    <time_frame>Baseline</time_frame>
    <description>Prior to start of intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL function (RCT) as measured by cholesterol efflux.</measure>
    <time_frame>Week 6</time_frame>
    <description>End of treatment 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL function (RCT) as measured by cholesterol efflux.</measure>
    <time_frame>Week 14</time_frame>
    <description>End of treatment 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HDL function (RCT) as measured by cholesterol efflux.</measure>
    <time_frame>Week 22</time_frame>
    <description>End of treatment 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HDL particle size</measure>
    <time_frame>Baseline</time_frame>
    <description>Prior to start of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL particle size</measure>
    <time_frame>Week 6</time_frame>
    <description>End of treatment 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL particle size</measure>
    <time_frame>Week 14</time_frame>
    <description>End of treatment 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL particle size</measure>
    <time_frame>Week 22</time_frame>
    <description>End of treatment 3</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lipids (including lipoproteins and apolipoproteins)</measure>
    <time_frame>Baseline</time_frame>
    <description>Prior to start of intervention</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipids (including lipoproteins and apolipoproteins)</measure>
    <time_frame>Week 6</time_frame>
    <description>End of treatment 1</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipids (including lipoproteins and apolipoproteins)</measure>
    <time_frame>Week 14</time_frame>
    <description>End of treatment 2</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipids (including lipoproteins and apolipoproteins)</measure>
    <time_frame>Week 22</time_frame>
    <description>End of treatment 3</description>
  </other_outcome>
  <other_outcome>
    <measure>Central blood pressure (including augmentation index, pulse pressure, and pulse wave velocity).</measure>
    <time_frame>Baseline</time_frame>
    <description>Prior to start of intervention</description>
  </other_outcome>
  <other_outcome>
    <measure>Central blood pressure (including augmentation index, pulse pressure, and pulse wave velocity).</measure>
    <time_frame>Week 6</time_frame>
    <description>End of treatment 1</description>
  </other_outcome>
  <other_outcome>
    <measure>Central blood pressure (including augmentation index, pulse pressure, and pulse wave velocity).</measure>
    <time_frame>Week 14</time_frame>
    <description>End of treatment 2</description>
  </other_outcome>
  <other_outcome>
    <measure>Central blood pressure (including augmentation index, pulse pressure, and pulse wave velocity).</measure>
    <time_frame>Week 22</time_frame>
    <description>End of treatment 3</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Soy 25g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Soy protein powder (25g/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soy 50g</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Soy protein powder 50 g/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control powder</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soy Protein Powder (25g/d)</intervention_name>
    <description>Participants will consume 25g soy protein powder daily for a 6 week treatment period.</description>
    <arm_group_label>Soy 25g</arm_group_label>
    <arm_group_label>Soy 50g</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will consume a placebo control powder containing 0g soy protein powder daily for a 6 week treatment period.</description>
    <arm_group_label>Soy 25g</arm_group_label>
    <arm_group_label>Soy 50g</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Soy Protein Powder (50g/d)</intervention_name>
    <description>Participants will consume 50g soy protein powder daily for a 6 week treatment period.</description>
    <arm_group_label>Soy 25g</arm_group_label>
    <arm_group_label>Soy 50g</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and Female

          -  35-60 years old,with

          -  Systolic blood pressure greater than 120 mm Hg

          -  Diastolic blood pressure greater than 80 mm Hg

          -  BMI within 18-39 kg/m2 ,

          -  non smokers with

          -  no inflammatory diseases and

          -  not taking medication for high cholesterol, blood pressure, or glucose control

        Exclusion Criteria:

          -  Under 35 years of age or over 60 years old

          -  Systolic blood pressure &lt;120 or Diastolic blood pressure &lt;80

          -  smoker

          -  inflammatory disease

          -  BMI outside of 18-39kg/m2 range

          -  taking medication

          -  refusal to discontinue any other supplement use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Penny M Kris-Etherton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State University</name>
      <address>
        <city>University Park</city>
        <state>Pennsylvania</state>
        <zip>16802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2014</study_first_submitted>
  <study_first_submitted_qc>July 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2014</study_first_posted>
  <last_update_submitted>March 28, 2016</last_update_submitted>
  <last_update_submitted_qc>March 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Penn State University</investigator_affiliation>
    <investigator_full_name>Penny Kris-Etherton</investigator_full_name>
    <investigator_title>Distinguished Professor of Nutrition</investigator_title>
  </responsible_party>
  <keyword>soy</keyword>
  <keyword>hypertension</keyword>
  <keyword>HDL-C</keyword>
  <keyword>cholesterol efflux</keyword>
  <keyword>cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

